Ceralasertib (AZD6738)

For research use only. Not for use in humans.

目录号:S7693

Ceralasertib (AZD6738) Chemical Structure

CAS No. 1352226-88-0

Ceralasertib (AZD6738) 是一种口服具有活性的,选择性 ATR 激酶抑制剂,IC50 为 1 nM。Phase 1/2。

规格 价格 库存 购买数量  
10mM (1mL in DMSO) RMB 2432.43 现货
RMB 1615.57 现货
RMB 5700.55 现货
RMB 12039.3 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的Ceralasertib (AZD6738)发表文献56篇:

产品安全说明书

ATM/ATR抑制剂选择性比较

生物活性

产品描述 Ceralasertib (AZD6738) 是一种口服具有活性的,选择性 ATR 激酶抑制剂,IC50 为 1 nM。Phase 1/2。
靶点
ATR [1]
(Cell-free assay)
1 nM
体外研究

在四个Kras突变细胞系:H23,H460,A549,和H358中,AZD6738抑制ATR激酶活性,并损害细胞活性。在ATM缺失的H23细胞中,AZD6738强烈增强顺铂诱导快速细胞死亡的作用。[1]在p53 或 ATM缺失的细胞中,AZD6738治疗引起复制叉停滞和未修复DNA损伤的积累,导致有丝分裂障碍,从而使细胞死亡。[2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
LICR-LON-HN4 and LICR-LON-HN5 cells M2XC[mZ2dmO2aX;uJIF{e2G7 M3;h[FAvODNuIECuNUwhOC5|LDCxMEA{NCBzMDFOwG0> NUTuRYFGSVqGNkezPEBqdmirYnn0bY9vKG:oIFHUVkB1cHKxdXfoJIxwe3Nib3[g[I94dnO2cnXhcUBxcG:|cHjvdplt[XSrb36gc4YhS0iNMTDvckBU\XJ|NEWu Ml:0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzByNUe4PVAoRjNyMEW3PFkxRC:jPh?=
K8484 cells MkPPSpVv[3Srb36gZZN{[Xl? NFLVWFUzKM7:TR?= MUO3JIhwfXK| NV2zR3ZkUW5iS{i0PFQh[2WubIOsJGFbTDZ5M{igZZQhOiEEtV2gZ49ueGyndHXsfUBxemW4ZX70[YQh\2WvY3n0ZYJqdmVvaX7keYNm\CCFaHuxJJBpd3OyaH;yfYxifGmxbjDvckBU\XKrbnWgN|Q2NCC2aHWg[I94dnO2cnXhcUBCXFJidHHy[4V1Ng>? M4nwblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7OEmxOFg5Lz5{OUi5NVQ5QDxxYU6=
SNU-601 cells NGjIZ4pE\WyuIHfyc5d1cCCrbnjpZol1cW:wIHHzd4F6 MXywMVEh|ryvb3yvUC=> NIr1RXA2KGSjeYO= NVP2cWhlXGinIGOgZY5lKHO3Yj3HNUBxd3C3bHH0bY9veyCxZjDTUnUuPjBzIHPlcIx{KHencnWg[JJidWG2aXPhcIx6KGGwZDDkc5NmNWSncHXu[IVvfGy7IHnuZ5Jm[XOnZDDifUBCYkR4N{O4Mi=> M17Nb|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MUO4NFM1Lz5{OEGzPFA{PDxxYU6=
breast cancer cell lines MYPD[YxtKGe{b4f0bEBqdmirYnn0bY9vKGG|c3H5 NY\tbGYyOC5zMkWsJFAvOjVuIECuOUBidmRiMT6wJO69VQ>? MYO1JIRigXN? NFvB[XlKSzVyII\hcJVmeyC{YX7n[YQh\nKxbTCwMlMhfG9iPkGg{txud2xxTB?= MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzVyMUGxN{c,Ojd3MEGxNVM9N2F-
LoVo cells NVHi[Yh3TnWwY4Tpc44h[XO|YYm= M3H1RlI1KGh? Mn2wVoVlfWO2aX;uJIlvKGOnbHygZ492dnR9IHGgdJJweG:{dHnvckBw\iC2aHWgZ4VtdCCyb4D1cIF1cW:wIHHy[UApcW5iYXTkbZRqd25idH:gZ4VtdCCleXPs[UBienKnc4SpJJVv\GW{Z3;pcoch[XCxcITvd4l{KHeqZX6g[Zhxd3OnZDD0c{BlenWpIHH0JINwdmOnboTyZZRqd26|IHfy[YF1\XJidHjhckA{6oDLzszN M1zabFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4M{GwN|EzLz5{NkOxNFMyOjxxYU6=
HT29 cells MWfGeY5kfGmxbjDhd5NigQ>? NUC4PXJRPjBibXnudy=> MWXJR|UxKD1iMD6wO|Qh|ryP NUHhRZdHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CzOFY4PzJpPkOwN|Q3Pzd{PD;hQi=>
LoVo cells MojkR5l1d3SxeHnjbZR6KGG|c3H5 MVq3NkBpenN? MkXBS2k2OCB;IECuOFQh|ryP NYLXNnFvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CzOFY4PzJpPkOwN|Q3Pzd{PD;hQi=>
LoVo cells M3\BfGZ2dmO2aX;uJIF{e2G7 MlyyNlUhdWdxa3e= NXXqTWZDQCCqcoO= MorSR5AhRSByLke0JO69VQ>? NYTlZ2FJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CzOFY4PzJpPkOwN|Q3Pzd{PD;hQi=>
LoVo cells M4ntUmZ2dmO2aX;uJIF{e2G7 MX[1NEBu\y:tZx?= NVOzbGs3QCCqcoO= MkDtR5AhRSB{LkKg{txO M2j2S|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyM{S2O|czLz5|MEO0Olc4OjxxYU6=
HT-29 cells Mnq4R5l1d3SxeHnjbZR6KGG|c3H5 MXq3NkBpenN? MXfHTVUxKD1iMj62JO69VQ>? NUjLR3J[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CzOFY4PzJpPkOwN|Q3Pzd{PD;hQi=>
LoVo cells M2S2SGZ2dmO2aX;uJIF{e2G7 MnPFO|UhdWdxa3e= M4HQOVghcHK| MUfDdEA:KDJwNjFOwG0> MnHxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzB|NE[3O|IoRjNyM{S2O|czRC:jPh?=
MDA-MB-468 cells MVXGeY5kfGmxbjDhd5NigQ>? MX\JR|UxKD1iNT63JO69VQ>? NIf6VXQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MEO0Olc4Oid-M{CzOFY4PzJ:L3G+

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
ATM pSer1981 / ATM / ATR / Chk1 pSer345 / Chk1 / Chk2 pThr68 / Chk2; 

PubMed: 26563132     


TP53/ATM wild-type (TP53/ATM-wt) primary CLL cells cocultured with and CLL cells, both CII-GFPsh and CII-ATMsh were treated with AZD6738 (1 μM) for 2 hours, or left untreated, prior to exposure to HU (1 mM) or IR (6 Gy) for a further 5 hours. AZD6738 treatment inhibited ATR signaling as indicated by a reduction in HU-induced Chk1 phosphorylation (lanes 3 vs 4 and 9 vs 10). In ATM-proficient CLL cells, this also led to ATM activation as evidenced by ATM phosphorylation and Chk2 phosphorylation (lane 3 vs 4). 

pCHK1 / pCDC25c / pRPA32 / γH2AX / pHH3 / cleaved caspase-3 / RAD51; 

PubMed: 29605721     


MDA-231 or Hs578t cells were treated with 50 nM or 100 nM of AZD1775 with or without 500 nM of AZD6738 for 24 h. After treatment, western blot was performed using anti-γH2AX, anti-pCHK1 (S345), anti-CHK1, anti-pCDC25c (S216), anti-CDC25c, anti-pHH3, anti-RAD51 anti-pRPA32 (S4/S8), anti-cleaved-caspase 3, and anti-GAPDH antibodies. 

26563132 29605721
Immunofluorescence
53BP1; 

PubMed: 26563132     


Cells treated with AZD6738 (1 μM) for 48 hours were labeled with anti-53BP1 antibodies, and at least 200 cells were then analyzed in each sample using a ×60 lens. AZD6738 treatment led to an accumulation of 53BP1 foci in Mec1 and ATMi pretreated CII cells and an accumulation of 53BP1 bodies in CII cells without ATMi pretreatment.

γH2AX / RAD51; 

PubMed: 29605721     


MDA-231 cells were treated with 50 nM or 100 nM of AZD1775 with or without 500 nM of AZD6738 for 24 h. Cells were probed with anti-γH2AX and anti-RAD51 antibodies. Scale bar: 5 μm. 

26563132 29605721
Growth inhibition assay
IC50; 

PubMed: 28062704     


Cell line IC50 values assessed for growth inhibition in a 72-hour MTT assay

Cell viability; 

PubMed: 26563132     


CII-GFPsh, CII-ATMsh (ATM-deficient), and Mec1 (p53-defective) cells were treated with AZD6738 for 4 days, and viability was measured using the CellTiter-Glo assay. Surviving fraction is expressed relative to untreated controls. AZD6738 induced significantly greater dose-dependent cytotoxicity with significantly lower AZD6738 EC50 in CII-ATMsh and Mec1 cells compared with CII-GFPsh cells.

28062704 26563132
体内研究 在负荷H460和H23肿瘤的裸鼠中,AZD6738 (50 mg/kg, p.o.)导致肿瘤生长抑制(TGI),结合顺铂引起ATM缺失的H23肿瘤快速退化。[1]在负荷LoVo异种移植物的裸鼠中,AZD6738 (50 mg/kg) + IR (2 Gy)的组合避免了毒性,同时仍保持疗效。[3]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

细胞实验:[1]
- 合并
  • Cell lines: H23,H460,A549,和 H358 细胞
  • Concentrations: ~30 μM
  • Incubation Time: 48小时
  • Method: 细胞在白色壁,透明底的96孔板中与指示剂量的AZD6738,cisplatin,gemcitabine,或它们的组合处理48小时。ATP水平通过CellTiter-Glo发光细胞活性试验和Safire2酶标仪测量代替品活性评估。进一步分析之前,原始数据对本底发光进行校正。对于AZD6738治疗,在GraphPad Prism 6中将对数转化(x=log(x))的数据归一化为未处理对照组的平均值,通过非线性回归(log(抑制剂) vs. 对可变斜率的响应值) 生成对数剂量响应曲线。GI50值,定义为Y = 50%时,X的剂量,根据剂量反应曲线推导得出。
    (Only for Reference)
动物实验: [1]
- 合并
  • Animal Models: 负荷 H23 或 H460 异种移植物的雌性无胸腺裸鼠
  • Dosages: 25 或 50 mg/kg
  • Administration: p.o.
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 82 mg/mL (198.78 mM)
Water Insoluble
Ethanol '41 mg/mL warmed
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
5% DMSO+40% propylene glycol+ddH2O
10mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 412.51
化学式

C20H24N6O2S

CAS号 1352226-88-0
储存条件 粉状
溶于溶剂
别名 N/A

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、SDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、SDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04704661 Recruiting Drug: Ceralasertib|Biological: Trastuzumab Deruxtecan Advanced Breast Carcinoma|Advanced Colon Carcinoma|Advanced Colorectal Carcinoma|Advanced Endometrial Carcinoma|Advanced Gastric Carcinoma|Advanced Gastroesophageal Junction Adenocarcinoma|Advanced Malignant Solid Neoplasm|Advanced Salivary Gland Carcinoma|Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Anatomic Stage IIIB Breast Cancer AJCC v8|Anatomic Stage IIIC Breast Cancer AJCC v8|Anatomic Stage IV Breast Cancer AJCC v8|Clinical Stage III Gastric Cancer AJCC v8|Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8|Clinical Stage IV Gastric Cancer AJCC v8|Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8|Clinical Stage IVA Gastric Cancer AJCC v8|Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8|Clinical Stage IVB Gastric Cancer AJCC v8|Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8|HER2 Positive Breast Carcinoma|Liver and Intrahepatic Bile Duct Carcinoma|Metastatic Breast Carcinoma|Metastatic Gastroesophageal Junction Adenocarcinoma|Metastatic Malignant Solid Neoplasm|Pathologic Stage III Gastric Cancer AJCC v8|Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IIIA Gastric Cancer AJCC v8|Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IIIB Gastric Cancer AJCC v8|Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IIIC Gastric Cancer AJCC v8|Pathologic Stage IV Gastric Cancer AJCC v8|Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8|Prognostic Stage III Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8|Prognostic Stage IIIB Breast Cancer AJCC v8|Prognostic Stage IIIC Breast Cancer AJCC v8|Prognostic Stage IV Breast Cancer AJCC v8|Stage III Colon Cancer AJCC v8|Stage III Colorectal Cancer AJCC v8|Stage III Major Salivary Gland Cancer AJCC v8|Stage III Uterine Corpus Cancer AJCC v8|Stage IIIA Colon Cancer AJCC v8|Stage IIIA Colorectal Cancer AJCC v8|Stage IIIA Uterine Corpus Cancer AJCC v8|Stage IIIB Colon Cancer AJCC v8|Stage IIIB Colorectal Cancer AJCC v8|Stage IIIB Uterine Corpus Cancer AJCC v8|Stage IIIC Colon Cancer AJCC v8|Stage IIIC Colorectal Cancer AJCC v8|Stage IIIC Uterine Corpus Cancer AJCC v8|Stage IIIC1 Uterine Corpus Cancer AJCC v8|Stage IIIC2 Uterine Corpus Cancer AJCC v8|Stage IV Colon Cancer AJCC v8|Stage IV Colorectal Cancer AJCC v8|Stage IV Major Salivary Gland Cancer AJCC v8|Stage IV Uterine Corpus Cancer AJCC v8|Stage IVA Colon Cancer AJCC v8|Stage IVA Colorectal Cancer AJCC v8|Stage IVA Major Salivary Gland Cancer AJCC v8|Stage IVA Uterine Corpus Cancer AJCC v8|Stage IVB Colon Cancer AJCC v8|Stage IVB Colorectal Cancer AJCC v8|Stage IVB Major Salivary Gland Cancer AJCC v8|Stage IVB Uterine Corpus Cancer AJCC v8|Stage IVC Colon Cancer AJCC v8|Stage IVC Colorectal Cancer AJCC v8|Stage IVC Major Salivary Gland Cancer AJCC v8|Unresectable Colorectal Carcinoma|Unresectable Gastroesophageal Junction Adenocarcinoma|Unresectable Malignant Solid Neoplasm National Cancer Institute (NCI) March 5 2021 Phase 1
NCT04361825 Enrolling by invitation Drug: Durvalumab Small Cell Lung Cancer Samsung Medical Center|AstraZeneca June 17 2020 Phase 2
NCT04298008 Recruiting Drug: AZD6738|Drug: Durvalumab Bile Duct Cancer|Chemotherapy Effect Seoul National University Hospital June 25 2020 Phase 2
NCT04298021 Recruiting Drug: AZD6738|Drug: Durvalumab|Drug: Olaparib Bile Duct Cancer|Chemotherapy Effect Seoul National University Hospital June 25 2020 Phase 2
NCT03669601 Recruiting Drug: AZD6738|Drug: Gemcitabine Cancer CCTU- Cancer Theme|AstraZeneca|Cambridge University Hospitals NHS Foundation Trust October 15 2019 Phase 1

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

ATM/ATR Signaling Pathway Map

相关ATM/ATR产品

Tags: 购买Ceralasertib (AZD6738) | Ceralasertib (AZD6738)供应商 | 采购Ceralasertib (AZD6738) | Ceralasertib (AZD6738)价格 | Ceralasertib (AZD6738)生产 | 订购Ceralasertib (AZD6738) | Ceralasertib (AZD6738)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID